95 related articles for article (PubMed ID: 24674725)
1. [The role of Foxo1 and ubiquitin-proteasome system markers in muscle atrophy caused by chronic kidney disease].
Yin J; Huang J; Yuan W; Gu L; Wang L; Shang M
Zhonghua Nei Ke Za Zhi; 2014 Jan; 53(1):31-4. PubMed ID: 24674725
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
3. Influence of divergent exercise contraction mode and whey protein supplementation on atrogin-1, MuRF1, and FOXO1/3A in human skeletal muscle.
Stefanetti RJ; Lamon S; Rahbek SK; Farup J; Zacharewicz E; Wallace MA; Vendelbo MH; Russell AP; Vissing K
J Appl Physiol (1985); 2014 Jun; 116(11):1491-502. PubMed ID: 24458747
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the FoxO1/MuRF1/Atrogin-1 Signaling Pathway in the Oxidative Stress-Induced Atrophy of Cultured Chronic Obstructive Pulmonary Disease Myotubes.
Pomiès P; Blaquière M; Maury J; Mercier J; Gouzi F; Hayot M
PLoS One; 2016; 11(8):e0160092. PubMed ID: 27526027
[TBL] [Abstract][Full Text] [Related]
5. Excessive glucocorticoid-induced muscle MuRF1 overexpression is independent of Akt/FoXO1 pathway.
Wang XJ; Xiao JJ; Liu L; Jiao HC; Lin H
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29046370
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of atrogenic and ubiquitin proteasome component genes with exercise: effect of different loading patterns and repeated exercise bouts.
Nedergaard A; Vissing K; Overgaard K; Kjaer M; Schjerling P
J Appl Physiol (1985); 2007 Nov; 103(5):1513-22. PubMed ID: 17690190
[TBL] [Abstract][Full Text] [Related]
7. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease.
Doucet M; Russell AP; Léger B; Debigaré R; Joanisse DR; Caron MA; LeBlanc P; Maltais F
Am J Respir Crit Care Med; 2007 Aug; 176(3):261-9. PubMed ID: 17478621
[TBL] [Abstract][Full Text] [Related]
8. Regulation of ubiquitin proteasome pathway molecular markers in response to endurance and resistance exercise and training.
Stefanetti RJ; Lamon S; Wallace M; Vendelbo MH; Russell AP; Vissing K
Pflugers Arch; 2015 Jul; 467(7):1523-1537. PubMed ID: 25104573
[TBL] [Abstract][Full Text] [Related]
9. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes.
Castillero E; Alamdari N; Lecker SH; Hasselgren PO
Metabolism; 2013 Oct; 62(10):1495-502. PubMed ID: 23866982
[TBL] [Abstract][Full Text] [Related]
10. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
11. Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy.
Léger B; Cartoni R; Praz M; Lamon S; Dériaz O; Crettenand A; Gobelet C; Rohmer P; Konzelmann M; Luthi F; Russell AP
J Physiol; 2006 Nov; 576(Pt 3):923-33. PubMed ID: 16916907
[TBL] [Abstract][Full Text] [Related]
12. Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients.
Léger B; Senese R; Al-Khodairy AW; Dériaz O; Gobelet C; Giacobino JP; Russell AP
Muscle Nerve; 2009 Jul; 40(1):69-78. PubMed ID: 19533653
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms involved in 3',5'-cyclic adenosine monophosphate-mediated inhibition of the ubiquitin-proteasome system in skeletal muscle.
Gonçalves DA; Lira EC; Baviera AM; Cao P; Zanon NM; Arany Z; Bedard N; Tanksale P; Wing SS; Lecker SH; Kettelhut IC; Navegantes LC
Endocrinology; 2009 Dec; 150(12):5395-404. PubMed ID: 19837877
[TBL] [Abstract][Full Text] [Related]
14. Branched-chain amino acids reduce hindlimb suspension-induced muscle atrophy and protein levels of atrogin-1 and MuRF1 in rats.
Maki T; Yamamoto D; Nakanishi S; Iida K; Iguchi G; Takahashi Y; Kaji H; Chihara K; Okimura Y
Nutr Res; 2012 Sep; 32(9):676-83. PubMed ID: 23084640
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of inducible nitric oxide synthase attenuates immobilization-induced skeletal muscle atrophy in mice.
Bae SK; Cha HN; Ju TJ; Kim YW; Kim HS; Kim YD; Dan JM; Kim JY; Kim SD; Park SY
J Appl Physiol (1985); 2012 Jul; 113(1):114-23. PubMed ID: 22518831
[TBL] [Abstract][Full Text] [Related]
16. Modulation of autophagy and ubiquitin-proteasome pathways during ultra-endurance running.
Jamart C; Francaux M; Millet GY; Deldicque L; Frère D; Féasson L
J Appl Physiol (1985); 2012 May; 112(9):1529-37. PubMed ID: 22345427
[TBL] [Abstract][Full Text] [Related]
17. Dystrophin involved in the susceptibility of slow muscles to hindlimb unloading via concomitant activation of TGF-β1/Smad3 signaling and ubiquitin-proteasome degradation in mice.
Zhang P; Li W; Liu H; Li J; Wang J; Li Y; Chen X; Yang Z; Fan M
Cell Biochem Biophys; 2014 Nov; 70(2):1057-67. PubMed ID: 24839113
[TBL] [Abstract][Full Text] [Related]
18. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
Schulze PC; Fang J; Kassik KA; Gannon J; Cupesi M; MacGillivray C; Lee RT; Rosenthal N
Circ Res; 2005 Sep; 97(5):418-26. PubMed ID: 16051886
[TBL] [Abstract][Full Text] [Related]
19. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study.
Gielen S; Sandri M; Kozarez I; Kratzsch J; Teupser D; Thiery J; Erbs S; Mangner N; Lenk K; Hambrecht R; Schuler G; Adams V
Circulation; 2012 Jun; 125(22):2716-27. PubMed ID: 22565934
[TBL] [Abstract][Full Text] [Related]
20. PPARβ/δ regulates glucocorticoid- and sepsis-induced FOXO1 activation and muscle wasting.
Castillero E; Alamdari N; Aversa Z; Gurav A; Hasselgren PO
PLoS One; 2013; 8(3):e59726. PubMed ID: 23555761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
